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Background: This study tested the hypothesis that rosuvastatin reduces thrombus burden through inhibiting inflammation
and suppressing reactive oxygen species (ROS) generation in an inferior vena cava stenosis (IVCST)-induced deep
vein thrombosis (DVT) rat model.
Methods: 12-week-old male Sprague–Dawley rats (n = 24) were equally divided into sham control (group 1:
laparotomy only), IVCST (group 2: IVC stenosis), and IVCST + rosuvastatin (20 mg/kg/day, orally after induction of
IVC stenosis) (group 3). IVC diameter was measured by days 0 and 14 and the right hindlimb thickness was
measured by day 0, 7, and 14 prior to scarifying the animals.
Results: The results showed significantly increased IVC diameter and hindlimb thickness in group 2 than in groups 1
and 3, and significantly increased in group 3 than in group 1 by day 14 after the procedure (all p < 0.001). Additionally,
WBC count and prevalence of helper T cells, cytotoxic T cells, regulatory T cells, and early and late apoptotic
mononuclear cells (MNCs) in circulation were significantly higher in group 2 than in group 1, and were significantly
suppressed in group 3 after treatment (all p < 0.001). Furthermore, inflammation at cellular (CD68+ cells) and protein
(MMP-9, TNF-α) levels, oxidative stress (oxidized protein) and reactive oxygen species (NOX-1, NOX-2) in IVC also
showed similar changes as those of immune cells in circulation among the three groups (all p < 0.01).
Conclusion: Rosuvastatin treatment significantly reduced IVC thrombus burden through inhibiting inflammatory
response and oxidative stress in a rodent model of DVT.Introduction
Venous thromboembolic disease (VTED) (i.e., pulmonary
embolism and deep vein thrombosis) affects approximately
100 persons in a population of 100,000 per year [1]. The
incidence increases with age, rising exponentially from less
than 5 per 100,000 per year in those under 15 of age to
over 500 per 100,000 per year in those aged over 80 years
[1]. VTED consists of a divergent spectrum of clinical
disorders, from asymptomatic deep vein thrombosis (DVT)
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reproduction in any medium, provided the orembolism (PE) [1-3]. DVT that occurs or extends above
the knee (i.e., proximal DVT) carry a significant risk of
propagation to form acute or chronic recurrent PE, result-
ing in acute cardiac or respiratory compromise or
pulmonary arterial hypertension and, in severe cases,
death [1-7]. In addition, VTED may itself be associated
with significant morbidity through the development of
post-thrombotic syndrome (PTS) [8].
Studies have extensively renewed the concept of Virchow’s
triad that describes the three factors, i.e., hypercoagulability,
stasis, and endothelial injury as the fundamental contribu-
tors to the development of venous thrombosis [9-11]. Actu-
ally, extensive works have shown that venous and arterial
thrombosis involves more complicated mechanisms other
than that included in Virchow’s triad [9-11]. Accordingly,
more detailed investigation into the mechanism underlying
Virchow’s triad has been recommended [9-11]. In fact, it has. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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various molecular-cellular components [9-11]. For instance,
injury of the endothelial cells and stimulation of the
monocytes lead to the release of inflammatory cytokines
[11]. The pro-inflammatory mediators including bacterial
lipopolysaccharide, and the cytokines interleukin-1 and
tumor necrosis factor-α (TNF-α), in turn, induce and aug-
ment the pro-coagulant activity (i.e., thrombin gene-
ration) [11-14]. Interestingly, a recent clinical trial, i.e., the
secondary analyses of the JUPITER trial, in which 17,802
apparently healthy subjects were randomly allocated to
receive either rosuvastatin daily or placebo, provided evi-
dence that statin therapy reduced the incidence of DVT
[15]. Although the mechanism underlying the therapeutic
effect remains uncertain, the findings suggest a positive
association between inflammation and DVT. For clarifying
the potential role of rosuvastain therapy in reducing veno-
thrombosis and molecular-cellular mechanisms involved,
a rodent model of inferior vena cava (IVC) stenosis to
create a DVT scenario was utilized in the current study.
Methods
Ethics
All animal experimental procedures were approved by the
Institute of Animal Care and Use Committee at Kaohsiung
Chang Gung Memorial Hospital and performed in accord-
ance with the Guide for the Care and Use of Laboratory
Animals (NIH publication No. 85–23, National Academy
Press, Washington, DC, USA, revised 1996).
Animal model of acute inferior vena cava thrombosis and
treatment
Pathogen-free, adult male Sprague–Dawley (SD) rats weigh-
ing 375–400 g (Charles River Technology, BioLASCO
Taiwan Co. Ltd., Taiwan) were equally divided into three
groups (n = 8 in each group): Group 1 (Sham control, SC):
laparotomy only; Group 2 (DVT only): laparotomy + IVC
stenosis (IVCST); and Group 3 (DVT + Rosu): laparot-
omy + IVCST + rosuvastatin (20 mg/kg/day) by gavage.
The dosage of rosuvastatin for the animals was based
on our recent study [16]. The treatment was initiated
just after the IVC stenosis procedure and continued for
14 days. The rats were sacrificed on day 14 after laparot-
omy and measurement of the IVC diameter.
Additionally, for assessing acute phase of thrombus
formation and changes of IVC diameter at day 2 after
DVT induction, another 8 rats in each group were
utilized and they were sacrificed at day 2 after parame-
ters were collected.
Laparotomy and IVC stenosis were performed after
anesthesia of the rats by inhalation of 2.0% isoflurane.
Briefly, the rat was placed in a supine position on a
warming pad at 37°C with the abdomen shaved. Under
sterile conditions, the abdomen was opened and IVCwas exposed, followed by tying a 23 gauge needle over
the IVC just below the level of left renal vein with 4–0
silk in each rat. Additionally, to avoid the formation of
collateral circulation that would attenuate the thrombus-
burden formation, the larger side branches were ligated
and those observable small side branches/capillaries
were carefully cauterized during the procedure. After the
procedure, the abdominal wound was closed and the
animal was allowed to recover from anesthesia in a portable
animal intensive care unit (ThermoCare®) for 24 hours.
Assessment of IVC diameter and palm thicknes
After the first laparotomy prior to IVC stenosis, the
diameter of IVC was measured at three levels 1 mm
apart. Additionally, by day 14 just prior to the sacrificing
the animals, the diameter of IVC below the stricture
level with an interval of 1 mm was measured at three
levels again after second laparotomy. The parameters
were summated and then divided by 3 for each rat at the
two time points, respectively.
To determine the severity of hindlimb edema caused
by IVC obstruction, the hindlimb thickness (i.e. the
distance between the sole and instep) in each rat was
measured with a digital caliper at days 0, 7 and 14 just
before sacrificing the animals.
Circulating White Blood Cell (WBC) count and flow
cytometric quantification of helper T cells, cytotoxic T
cells, and regulatory T cells (Tregs)
By days 2, 6 and 14 prior to sacrificing the animals (i.e., n = 8
for each group in each time interval to be sacrificed), per-
ipheral blood mononuclear cells (PBMCs) were obtained
from the tail vein using a 27# needle in each rat for de-
termining the WBC count. In addition, PBMCs and
splenocytes (1.0 x 106 cells) were triple-stained with FITC-
anti-CD3 (BioLegend), PE-anti-CD8a (BD Bioscience),
and PE-Cy™5 anti-CD4 (BD bioscience). To identify
CD4+CD25+Foxp3+ Tregs, PBMCs and splenocytes were
triple-stained with Alexa Fluor® 488-anti-CD25 (Bio-
Legend), PE-anti-Foxp3 (BioLegend), and PE-Cy™5 anti-
CD4 (BD bioscience) according to the manufacturer’s
protocol on the use of the Foxp3 Fix/Perm buffer set. The
numbers of CD3+CD4+ helper T cells, CD3+CD8+ cyto-
toxic T cells, and CD4+CD25+Foxp3+ Tregs were analyzed
using flow cytometry (FC500, Beckman Coulter).
Isolation of splenocytes and harvesting of IVC specimens
Splenocytes were obtained by homogenization of the
spleen using a Tenbroeck tissue grinder followed by
passage through a 0.4-mm-pore-size cell strainer to
obtain a single cell suspension. Splenocytes were then
suspended in RPMI and separated by Ficoll-paque™ Plus
(GE Healthcare).
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which were fixed with OCT (Tissue-Tek) for immuno-
histochemical (IHC)/immunofluorescent (IF) staining.
Other pieces were either fixed in 4% paraformaldehyde/
0.1% glutaradehyde PBS solution before being embed-
ded in paraffin blocks for hematoxylin–eosin staining
or stored at −80°C for protein analyses.
Western blot analysis of IVC distal to stenosis
Equal amounts (10–30 μg) of protein extracts from
the IVC were loaded and separated by SDS-PAGE
using 8-10% acrylamide gradients. Following electro-
phoresis, the separated proteins were transferred elec-
trophoretically to a polyvinylidene difluoride (PVDF)
membrane (Amersham Biosciences). Nonspecific pro-
teins were blocked by incubating the membrane in
blocking buffer (5% nonfat dry milk in T-TBS contain-
ing 0.05% Tween 20) overnight. The membranes were
incubated with monoclonal antibodies against polyclonal
antibodies against TNF-α (1: 1000, Cell Signaling), matrix
metalloproteinase (MMP)-9(1:5000, Abcam), NADPH
oxidase (NOX)-1 (1:1500, Sigma ) and NOX-2 (1:500,
Sigma). Signals were detected with horseradish peroxidase
(HRP)-conjugated goat anti-mouse, −rat, or -rabbit IgG.
The Oxyblot Oxidized Protein Detection Kit was
purchased from Chemicon (S7150). The procedure of
2,4-dinitrophenylhydrazine (DNPH) derivatization was
carried out on 6 μg of protein for 15 minutes according
to the manufacturer’s instructions. One-dimensional elec-
trophoresis was carried out on 12% SDS/polyacrylamide
gel after DNPH derivatization. Proteins were transferred
to nitrocellulose membranes which were then incubated
in the primary antibody solution (anti-DNP 1: 150) for
two hours, followed by incubation with the second anti-
body solution (1:300) for one hour at room temperature.
The washing procedure was repeated eight times within
40 minutes.
Immunoreactive bands were visualized by enhanced
chemiluminescence (ECL; Amersham Biosciences), which
was then exposed to Biomax L film (Kodak). For quantifi-
cation, ECL signals were digitized using Labwork software
(UVP). For oxyblot protein analysis, a standard control
was loaded on each gel.
Immunofluorescent (IF) and immunohistochemical (IHC)
studies
IF staining was performed for the examination of CD68+
cells in peri-IVC area using respective primary antibody
with irrelevant antibody being used as control. Three
sections of the IVC specimen were analyzed in each
rat. For quantification, three randomly selected HPFs
(200 x) were analyzed in each section. The mean num-
ber of cells per HPF for each animal was then deter-
mined by summation of all numbers divided by 9. AnIHC-based scoring system was adopted for the semi-
quantitative analysis of thrombomodulin expression in
endothelial cells of IVC (i.e. intimal layer) as a percent-
age of thrombomodulin in endothelial cells (score of
positively-stained thrombomodulin in endothelial cells:
0 = no stain%; 1 = <15%; 2 = 15 ~ 25%; 3 = 25 ~ 50%; 4 =
50 ~ 75%; 5= >75%-100%/per HPF in endothelial cells
in IVC). The analysis was performed in a blinded
fashion.
Histopathological study of thrombus burden in IVC distal
to the level of stenosis at Day 14 after the procedure
Hematoxylin and eosin (H & E) staining for light micro-
scopic analysis was used for studying the thrombus bur-
den inside IVC. Three serial sections of IVC 3 mm apart
were prepared at 4 μm thickness by Cryostat (Leica
CM3050S). The integrated area (μm2) of thrombus in
the slides was calculated using Image Tool 3 (IT3) image
analysis software (University of Texas, Health Science
Center, San Antonio, UTHSCSA; Image Tool for Win-
dows, Version 3.0, USA). Three selected sections were
quantified for each animal. Three randomly selected
high-power fields (HPFs) (100 x) were analyzed in each
section. After determining the number of pixels in each
thrombus area per HPF, the numbers of pixels obtained
from the three HPFs were summated. The procedure
was repeated in two other slides for each animal. The
mean pixel number per HPF for each animal was then
determined by summating all pixel numbers and divi-
ding by 9. The mean the integrated area (μm2) of
thrombus in IVC per HPF was obtained using a conver-
sion factor of 19.24 (1 μm2 represented 19.24 pixels).
Statistical analyses
Quantitative data are expressed as mean ± SD. Statis-
tical analysis was performed by ANOVA followed by
Bonferroni multiple-comparison post hoc test. All ana-
lyses were conducted using SAS statistical software for
Windows version 8.2 (SAS institute, Cary, NC). A prob-
ability value <0.05 was considered statistically significant.
Results
Serial changes of immune reactivity in circulation and
spleen at days 2. 6 and 14 Day after IVC stenosis
The time courses of circulating and splenic levels of im-
mune cells are shown in Table 1. By day 2, the circulat-
ing level of CD3+/CD4+ helper T cells did not differ
among groups 1 (sham control), group 2 (IVC stenosis)
and 3 (IVC stenosis + rosuvastatin). However, by day 6,
this biomarker was higher in groups 2 and 3 than in
group 1, but it showed no difference between groups 2
and 3. Additionally, by day 14, this biomarker was
significantly higher in group 2 than in groups 1 and 3,
and significantly higher in group 3 than in group 1.
Table 1 Time courses of immune cell expressions in








Day 2 18.9 ± 1.0 19.5 ± 0.9 19.3 ± 0.9 0.347
Day 6 17.8 ± 0.6a 24.8 ± 0.6b 23.2 ± 0.6b <0.001
Day 14 17.6 ± 0.9a 24.5 ± 0.7b 21.3 ± 0.3c <0.001
CD3+/CD8+ cytotoxic
T (%)
Day 2 8.9 ± 0.4 9.2 ± 0.8 9.6 ± 0.7 0.439
Day 6 8.2 ± 0.9a 11.2 ± 0.7b 11.1 ± 0.6b <0.02
Day 14 8.3 ± 1.1a 14.8 ± 0.4b 12.1 ± 0.5c <0.001
CD4+CD25+ Foxp3+
Tregs (%)
Day 2 2.1 ± 0.3 2.3 ± 0.1 2.1 ± 0.1 0.478
Day 6 2.1 ± 0.2a 3.0 ± 0.03b 2.7 ± 0.06c <0.01





Day 2 20.5 ± 0.1 20.7 ± 1.2 21.2 ± 1.4 0.641
Day 6 20.8 ± 0.1 21.8 ± 0.4 21.5 ± 0.7 0.668
Day 14 21.5 ± 0.1 21.7 ± 0.5 21.1 ± 0.6c 0.485
CD3+/CD8+ cytotoxic
T (%)
Day 2 13.9 ± 0.9 14.5 ± 0.4 14.2 ± 1.2 0.397
Day 6 14.3 ± 0.3a 15.8 ± 0.2b 15.4 ± 0.1b <0.05
Day 14 13.6 ± 0.9a 16.8 ± 0.4b 14.3 ± 0.2a <0.008
CD4+CD25+ Foxp3+
Tregs (%)
Day 2 7.7 ± 0.3a 9.0 ± 0.3b 8.4 ± 0.4a,b <0.02
Day 6 7.9 ± 0.3a 9.4 ± 0.5b 9.5 ± 0.6b <0.01
Day 14 7.5 ± 0.3a 12.9 ± 0.4b 9.2 ± 0.5c <0.001
Data are expressed as% of mean± SD.
DVT = deep vein thrombosis; Rosu = rosuvastatin.
Sham control = group 1, DVT = group 2, DVT-Rosu = group 3.
All statistical analyses were performed by one-way ANOVA, followed by Bonferroni
multiple comparison post hoc test. Letters (a, b, c) indicate significance (at 0.05 level).
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lating levels of CD3+/CD8+ cytotoxic T cells showed
an identical pattern of CD3+/CD4+ helper T cells
among the three groups in these different time inter-
vals, respectively.
By days 2, the circulating level of CD4 + CD25 + Foxp3+
Tregs, an index of immune down-regulation, was similar
among the three groups. However, by days 6 and 14, the
circulating levels of this parameter showed an identicalpattern of CD3+/CD4+ helper T cells at the interval of
day 14 among the three groups.
By days 2, 6 and 14 after DVT induction, the splenic
level of CD3+/CD4+ helper T cells showed no difference
among the three groups. Additionally, by day 2, the
splenic level of CD3+/CD8+ cytotoxic T cells did not
differ among the three groups. However, by day 6 and
14, the splenic level of this biomarker was significantly
higher in group 2 than in groups 1 and 3, and signifi-
cantly higher in group 2 than in group 1.
By day 2, the splenic level of CD4 + CD25 + Foxp3+
Tregs was significantly higher in group 2 than in group
1, but it showed no difference between groups 2 and 3
or between groups 1 and 3. By day 6, the splenic level of
this biomarker was significantly higher in groups 2 and 3
than in group 1, but it showed no difference between
groups 2 and 3. By day 14, the splenic level of this bio-
marker was significantly higher in groups 2 and 3 than
in group 1, and significantly higher in group 2 than in
group 3.
Circulating WBC count, early and late mononuclear cell
(MNC) apoptosis in the circulation at Day 14 after IVC
stenosis
By day 2, the circulating levels of white blood cell (WBC)
count and neutrophils (Figure 1B) were significantly
higher in group 2 than in groups 1 and 3, and signifi-
cantly higher in group 3 than in group 1 (Figure 1A).
Additionally, the circulating level of lymphocytes (Figure 1C)
were significantly lower in groups 2 and 3 than in group 1,
but it showed no difference between the former two groups.
By day 14, the circulating white blood cell (WBC) level
was significantly higher in group 2 than in groups 1 and
3, but it showed no difference between group 1 and
group 3 (Figure 1D). However, the circulating levels of
neutrophils (Figure 1E) and lymphocytes (Figure 1F) did
not differ among the three groups.
By day 2, flow cytometry revealed the degrees of early
(Figure 2A) and late (Figure 2B) apoptosis markers in
circulating MNCs were higher in groups 2 and 3 than
group 1, but it showed no difference between former
two groups. Moreover, by day 14, flow cytometry re-
vealed that the degree of early apoptosis in circulating
MNCs was higher in group 2 than in groups 1 and 3,
and significantly higher in group 3 than in group 1
(Figure 2C). In addition, the degree of late apoptosis of
MNCs in circulation displayed an identical pattern
compared to that of early apoptosis among three
groups, although the incidence of late apoptosis was
lower than that of early apoptosis (Figure 2D).
Time courses of circulating levels of inflammatory cells
By day 2, the flow cytometric analysis showed that the cir-
culating level of CD11+ cells, an indicator of inflammation
Figure 1 Levels of circulating WBC count, neutrophils and lymphocytes by days 2 and 14 after deep vein thrombosis (DVT)-induced
procedure (n = 8). A) Circulating level of white blood cell (WBC) count at day 2 after DVT-induced procedure. * vs. other groups with different
symbols (*, †, ‡), p < 0.001. B) Circulating level of neutrophils at day 2 after DVT-induced procedure. * vs. other groups with different symbols
(*, †, ‡), p < 0.01. C) Circulating level of neutrophils at day 2 after DVT-induced procedure. * vs. other groups with different symbols (*, †) P < 0.01.
D) circulating level of WBC count at day 14 after DVT-induced procedure. * vs. other groups with different symbols (*, †), p < 0.001. E) Circulating level
of neutrophils at day 14 after DVT-induced procedure. P > 0.5. F) Circulating level of neutrophils at day 2 after DVT-induced procedure. P > 0.5. Statistical
analysis using one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, ‡) indicate significance (at 0.05 level). DVT = deep
vein thrombosis, DVT + Rosu =DVT + rosuvastatin.
Figure 2 Circulating levels of early and late mononuclear cell
(MNC) apoptosis by days 2 and 14 after deep vein thrombosis
(DVT)-induced procedure (n = 8). A) Early MNC apoptosis
(Annexin-V+/PI-) at day 2 after DVT-induced procedure. * vs. other
groups with different symbols (*, †), p < 0.001. B) Late MNC apoptosis
(Annexin-V+/PI+) at day 2 after DVT-induced procedure. * vs. other
groups with different symbols (*, †, ‡), p < 0.001. C) Early MNC
apoptosis (Annexin-V+/PI-) at day 14 after DVT-induced procedure. *
vs. other groups with different symbols (*, †), p < 0.001. D) Late MNC
apoptosis (Annexin-V+/PI+) at day 14 after DVT-induced procedure. *
vs. other groups with different symbols (*, †), p < 0.001. Statistical analysis
using one-way ANOVA, followed by Bonferroni multiple comparison post
hoc test. Symbols (*, †, ‡) indicate significance (at 0.05 level). DVT = deep
vein thrombosis, DVT + Rosu =DVT + rosuvastatin.
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1, but it displayed no difference between the former two
groups (Figure 3A). Additionally, by days 6 and 14, this
biomarker were significantly higher in group 2 than in
groups 1 and 3, and significantly higher in group 3 than in
group 1 (Figure 3C and E). Additionally, by days 2, 6 and
14, circulating level of Ly-6G + cells, another index of
inflammation, exhibited an identical pattern of circulating
CD14+ cells among the three groups (Figure 3B, D and F).Pathological findings by days 2 and 14 after inferior vena
cava stenosis
Figure 4 shows the results of IVC diameter, an index of
IVC obstruction/swelling by day 0 (i.e., prior to IVC
stenosis) and day 14 (i.e., at the end of study period)
among group 1, group 2, and group 3. On day 0, the
IVC diameter did not differ among the three groups
(Figure 4B) (this parameter used in this work at day 0
was just to have a baseline for the study purpose). Be-
sides, it also showed no difference between days 0 and
14 among the group 1 animals (Figure 4A). However,
the IVC diameter was significantly increased on day 14
as compared with that on day 0 among group 2 and
group 3 animals, respectively (Figure 4A). Additionally,
by day 14 after IVC stenosis, this parameter was signifi-
cantly higher in group 2 than in groups 1 and 3, and no
different between groups 1 and 3 (Figure 4B). Thus, as
compared to day 0, the percentage of an increased in
IVC diameter by day 14 was remarkably higher in group
Figure 3 Flow cytometric quantification of circulating level of
inflammatory cells (CD11+, Ly-6G + cells) by days 2 and 14
after deep vein thrombosis (DVT)-induced procedure (n = 8).
A) Circulating number of CD11+ cells at day 2 after DVT-induced
procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.001.
B) Circulating number of Ly-6G + cells at day 2 after DVT-induced
procedure. * vs. other groups with different symbols (*, †, ‡), p <
0.001. C) Circulating number of CD11+ cells at day 6 after DVT-induced
procedure. * vs. other groups with different symbols (*, †), p < 0.001.
D) Circulating number of Ly-6G + cells at day 6 after DVT-induced
procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.0001.
E) Circulating number of CD11+ cells at day 14 after DVT-induced
procedure. * vs. other groups with different symbols (*, †), p < 0.001.
F) Circulating number of Ly-6G + cells at day 14 after DVT-induced
procedure. * vs. other groups with different symbols (*, †, ‡), p < 0.0001.
DVT = deep vein thrombosis, DVT + Rosu =DVT + rosuvastatin.
Figure 4 The diameter of inferior vena cava (IVC) at days 0
and 14 after deep vein thrombosis (DVT)-inducing procedure
(n = 8). A) The IVC diameter did not differ between day 0 and day
14 after DVT-induced procedure among the group 1 (sham control)
animals. However, IVC diameter was significantly higher at day 14 as
compared with day 0 among the group 2 (DVT) animals. * vs. day 0,
p < 0.01; Furthermore, the IVC diameter was also significantly higher at
day 14 as compared with day 0 among the group 3 (DVT + Rosu)
animals. * vs. day 0, p < 0.05. B) Prior to procedure, no difference
in baseline IVC diameter among group 1, group 2, and group 3
animals. However, by day 14 after DVT-induced procedure, the
IVC diameter was significantly higher in group 3 than in groups
1 and 3, and no different between groups 1 and 3. * vs. other
groups with different symbols (*, †, ‡), p < 0.001. C) By day 14
after DVT-induced procedure, the percentage of increased in IVC
diameter was remarkably higher in group 2 than in groups 1 and 3,
and notably higher in group 3 than in group 1. * vs. other groups with
different symbols (*, †, ‡), p < 0.0001. Statistical analysis in B) and C) using
one-way ANOVA, followed by Bonferroni multiple comparison post hoc
test. Symbols (*, †, ‡) indicate significance (at 0.05 level). DVT = deep vein
thrombosis, DVT + Rosu =DVT + rosuvastatin.
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than in group 1 (Figure 4C).
As expected, the acute phase of IVC diameter (Figure 5A)
and thrombus-burden formation (Figure 5B) at day 2 were
significantly higher in groups 2 and 3 than in group 1, and
significantly higher in group 2 than in group 3.
Figure 6 shows that hindlimb thickness, an indictor of
lower leg edema, was similar among the three groups on
day 0 (Figure 6B). The thickness also showed no differ-
ence at the time points of 0, 7, and 14 day among the
group 1 animals (Figure 6A). However, it was signifi-
cantly increased on days 7 and 14 as compared with that
on day 0 among group 2 animals (Figure 6A). Addition-
ally, this parameter was also increased on day 7 as
Figure 5 The diameter of inferior vena cava (IVC) and
thrombus-burden formation at day 2 after deep vein thrombosis
(DVT)-inducing procedure (n = 8). A) The IVC diameter was
significantly higher in group 2 than in groups 1 and 3, and
significantly higher in group 3 than in group 1. * vs. other groups
with different symbols (*, †, ‡), p < 0.001. B to D) Showing the H &
E staining for identification of thrombus formation in IVC in three
groups. E) Analytical results of thrombus burden, * vs. other groups
with different symbols (*, †, ‡), p < 0.0001. Statistical analysis in A) and
E) using one-way ANOVA, followed by Bonferroni multiple comparison
post hoc test. Symbols (*, †, ‡) indicate significance (at 0.05 level).
DVT = deep vein thrombosis, DVT + Rosu = DVT + rosuvastatin.
Figure 6 Hindlimb thickness at days 0, 7, and 14 after deep
vein thrombosis (DVT)-inducing procedure (n = 8). A) No
difference in hindlimb thickness by days 0, 7, and 14 among group
1 animals. Significantly increased hindlimb thickness on days 7 and
14 compared with day 0, without notable difference between latter
two time points among group 2 animals, p < 0.005. The hindlimb
thickness was also significantly higher on day 7 than on day 1, but it
exhibited no difference between days 0 and 14 or between days 7
and 14 among group 3 animals, p < 0.01. B). By day 0, no significant
difference noted in hindlimb thickness among the three groups. By
day 7, hindlimb thickness significantly increased in group 2 than in
groups 1 and 3, and significantly increased in group 3 than in group 1,
p < 0.01. By day 14, hindlimb thickness significantly increased in group
2 than in groups 1 and 3, and notably increased in group 3 than in
group 1, p < 0.01. C) By day 7, the percentage of increased hindlimb
thickness was significantly higher in group 2 than in groups 1 and 3,
and significantly higher in group 3 than in group 1, p < 0.001. By day
14, the percentage of increased hindlimb thickness was significantly
higher in group 2 than in groups 1 and 3, and significantly higher in
group 3 than in group 1. * vs. other groups with different symbols (*, †, ‡),
p < 0.0001. Statistical analysis in A), B) and C) using one-way ANOVA,
followed by Bonferroni multiple comparison post hoc test. Symbols
(*, †, ‡) indicate significance (at 0.05 level). DVT = deep vein thrombosis,
DVT + Rosu = DVT + rosuvastatin.
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http://www.journal-inflammation.com/content/11/1/27compared with that on the day 0 among group 3. How-
ever, this parameter did not differ on day 14 as compared
with day 0 or day 7. In addition, by days 7 and 14, the
thickness was significantly higher in group 2 than in
groups 1 and 3, and significantly higher in group 3 than in
group 3 at these two time points (Figure 6B). Further-
more, the percentage of increased in hindlimb thickness
was significantly higher in group 2 than in groups 1 and 3,
and notably higher in group 3 than in group 1 by days 7
and 14 after the DVT-induction procedure (Figure 6C).
Figure 7 shows the H & E staining of the thrombus bur-
den in IVC of the three groups by day 14 after IVC stenosis
(Figure 7A to C). The thrombus burden in IVC was signifi-
cantly higher in group 2 than that in groups 1 and 3, and
significantly higher in group 3 than in group 1 (Figure 7D).
Findings from Immunofluorescent (IF) and
Immunohistochemical (IHC) staining on Day 14 after
Inferior Vena Cava Stenosis
Figure 8 showed the results of IF and IHC staining of
IVC sections distal to the level of stenosis by day 14 afterthe procedure. IF staining revealed that the number of
peri-IVC CD68+ cells (i.e., macrophage marker), an index
of inflammation, was significantly higher in group 2 than
that in groups 1 and 3, and significantly higher in group 3
than in group 1 (Figure 8). Moreover, IHC staining
Figure 7 Thrombus burden in inferior vena cava (IVC) on day
14 after deep vein thrombosis (DVT)-inducing procedure (n = 8).
Microscopic (40 x) morphological analysis of IVC after H & E staining
showing significantly increased thrombus burden (yellow asterisk) in
group 2 (B) than in groups 1 (A) and 3 (C), and significantly increased
in group 3 than in group 1. AA = abdominal aorta. * vs. other groups
with different symbols (*, †, ‡), p < 0.001. Statistical analysis using
one-way ANOVA, followed by Bonferroni multiple comparison
post hoc test. Symbols (*, †, ‡) indicate significance (at 0.05 level).
Scale bars in right lower corner represent 200 μm. DVT = deep vein
thrombosis, DVT + Rosu = DVT + rosuvastatin.
Figure 8 Immunofluorescent (IF) and immunohistochemical
(IHC) staining of inferior vena cava (IVC) at day 14 after deep
vein thrombosis (DVT)-inducing procedure (n = 8). A to D)
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positive endothelial cells, an indicator of activated of
endothelial cells, around the IVC in group 2 than that
in groups 1 and 3, and significantly higher in group 3
than in group 1 (Figure 8).Microscopic (200 x) examination of IVC after IF staining showing
significantly higher number of CD68+ cells (i.e., macrophage) in peri-IVC
area (white arrows) in group 2 than in groups 1 and 3, and notably
higher in group 3 than in group 1. D) * vs. other groups with different
symbols (*, †, ‡), p < 0.0001. Scale bars in right lower corner represent
50 μm. E to H) Microscopic (200 x) examination of IVC after IHC
staining showing significantly higher number of positively stained
thrombomodulin endothelial cells (i.e., intimal layer) (black arrows)
in group 2 than in groups 1 and 3, and significantly higher in group 3 than
in group 1. H) * vs. other groups with different symbols (*, †, ‡), p < 0.0001.
Scale bars in right lower corner represent 50 μm. Statistical analysis in
D) and H) using one-way ANOVA, followed by Bonferroni multiple
comparison post hoc test. Symbols (*, †, ‡) indicate significance (at 0.05 level).
DVT = deep vein thrombosis, DVT + Rosu = DVT + rosuvastatin.Protein expressions of oxidized protein and inflammatory
biomarkers at Day 14 after inferior vena cava stenosis
By day 14 after the procedure, Western blot analysis
showed that the expression of oxidized protein, an indica-
tor of oxidative stress, was significantly higher in group 2
than that in groups 1 and 3, and significantly higher in
group 3 than that in group 1 (Figure 9). Besides, the pro-
tein expressions of TNF-α and MMP-9, two indices of
inflammation, exhibited an identical pattern compared
to that of oxidized protein among the three groups
(Figure 10).The protein expressions of Reactive Oxygen Species (ROS)
by Day 14 after inferior vena cava stenosis
By day 14, the protein expressions of NADPH oxidase
(NOX)-1 and NOX-2, two indicators of ROS, was sig-
nificantly higher in group 2 than that in groups 1 and 3,
and significantly higher in group 3 than that in group 1
(Figure 11).Discussion
One important finding in the current study is that, as
compared with sham controls (i.e., SC), the diameter of
IVC at days 2 and 14 after the procedure were remark-
ably higher in animals with IVC stricture (i.e., DVT
group). Additionally, we serially measured the hindlimb
thickness (i.e., at days 0, 7 and 14) and found that this
parameter was notably increased in DVT animals as
Figure 9 Protein expression of oxidative stress at day 14 after
DVT-inducing procedure (n =8). A) oxidative index (protein
carbonyls) among three groups of animals (1 = sham control, 2 = DVT
only, 3 = DVT + rosuvastatin). B) Remarkably increased expression of
oxidized protein (i.e., oxidative stress) in group 2 than in groups 1 and
3, and notably higher in group 3 than in group 1. * vs. other groups
with different symbols (*, †, ‡), p < 0.0001. [Note: Right lane and left
lane shown on the upper panel represent control oxidized molecular
protein standard and protein molecular weight (M.W.) marker,
respectively]. DNP = 1–3 dinitrophenylhydrazone. Statistical analysis
using one-way ANOVA, followed by Bonferroni multiple comparison
post hoc test. Symbols (*, †, ‡) indicate significance (at 0.05 level).
DVT = deep vein thrombosis, DVT + Rosu = DVT + rosuvastatin.
Figure 10 Protein expressions of inflammatory biomarkers at
day 14 after DVT-inducing procedure (n = 8). A) Significantly
higher protein expression of tumor necrosis factor (TNF)-α in group
2 than in groups 1 and 3, and significantly higher in group 3 than in
group 1. * vs. other groups with different symbols (*, †, ‡), p < 0.01.
B) Notably enhanced protein expression of matrix metalloproteinase
(MMP)-9 in group 2 than in groups 1 and 3, and significantly higher
in group 3 than in group 1. * vs. other groups with different symbols
(*, †, ‡), p < 0.01. Statistical analysis in A) and B) using one-way ANOVA,
followed by Bonferroni multiple comparison post hoc test. Symbols
(*, †, ‡) indicate significance (at 0.05 level). DVT = deep vein
thrombosis, DVT + Rosu = DVT + rosuvastatin.
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http://www.journal-inflammation.com/content/11/1/27compared to that of SC animals by days 7 and 14. To
the best of our knowledge, there are no animal model
(i.e., at the upright models, such us primates) in where
this can be successfully assessed in serial time intervals
after DVT procedure. We suggest that this is a novel
and important clinical-relevant finding. Furthermore,
another intriguing histopathological finding is that the
thrombus burden (i.e., the thrombus cross-sectional
area inside IVC) was notably higher in DVT group
than that in SC group. The results suggest that our
thrombus formation model was successfully created
through stenosis of IVC. The most important finding
of this study is that all of these anatomical and histo-
pathological changes in DVT group were substantially
reversed in DVT animals after receiving rosuvastatin
treatment for two weeks. Two clinical studies, one re-
cent randomized placebo-control trial [15] and one
previous retrospective study with a large sample size
[17], have demonstrated that statin therapy was associ-
ated with a significantly reduced risk of DVT. Addition-
ally, previously experimental studies have also revealed
that statin therapy remarkably reduced animal models of
DVT [18,19]. Accordingly, our findings supported those
from these two studies [15,17].
Abundant studies have revealed that, other than its
cholesterol-lowering effect, statin also possesses pleio-
tropic properties, especially those of anti-inflammation
Figure 11 Protein expressions of reactive oxygen species (ROS)
at day 14 after DVT-inducing procedure. A) Significantly higher
protein expression of NOX-1 in group 2 than in groups 1 and 3, and
significantly in group in group 3 than in group 1. * vs. other groups
with different symbols (*, †, ‡), p < 0.001. B) Notably increased protein
expression of NOX-2 in group 2 than in groups 1 and 3, and significantly
elevated in group 3 than in group 1. * vs. other groups with different
symbols (*, †, ‡), p < 0.001. Statistical analysis in A) and B) using one-way
ANOVA, followed by Bonferroni multiple comparison post hoc test.
Symbols (*, †, ‡) indicate significance (at 0.05 level). DVT = deep
vein thrombosis, DVT + Rosu = DVT + rosuvastatin.
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that the pathogenic mechanisms of VTED are complex,
including the participation of inflammatory cellular
elements and pro-inflammatory cytokines, rather than
the simple picture of Virchow’s triad [9-14]. One prin-
cipal finding in the present study is that time courses of
flow cytometric results showed circulating level CD14+
and Ly-6G + cells are remarkably higher in DVT animals
than that in SC animals. Another noteworthy finding in
the present study is that not only the cellular (CD68+ cells)
components, but also the molecular inflammatory com-
ponent (protein expressions of MMP-9, TNF-α) in IVC
specimen was found to be significantly higher in DVT
animals than that in SC animals. Of importance is that
all of these components were notably reduced in DVT
animals after receiving rosuvastatin treatment. Our
findings, therefore, reinforced those of previous studies
[9-14,20-22].
Interestingly, statin treatment has been shown to reduce
the activity, differentiation and proliferation of cytotoxic T
lymphocytes and the severity of graft-versus-host disease
[23,24]. Therefore, statin has been suggested to shed some
light on the pathogenesis of immunosuppressive graft-
versus-host disease [23,24]. An essential finding in the
present study is that the number of immune response cells
(CD3+/CD4+ helper T cells, CD3+/CD8+ cytotoxic T cells
and CD4 +CD25 + Foxp3+ Tregs) were markedly increased
in DVT animals compared with that in SC animals bydays 2, 6 and 14 after IVC-stenosis procedure. In addition,
the circulating level of WBC was also remarkably higher
in DVT than that in the SC group at days 2 and 14 after
the procedure. Consistently, the number of these in-
flammatory and immune response cells was remark-
ably reduced in DVT animals after rosuvastatin treatment.
Our findings are consistent with those of previous
studies [23,24].
One distinctive finding in the present study is that oxi-
dative stress (i.e., level oxidized protein by Oxyblot ana-
lysis) and expressions of ROS indices (NOX-1, NOX-2)
in IVC were remarkably increased in DVT animals, but
were significantly reduced in DVT animals after rosuvas-
tatin treatment. These findings corroborated those of
previous studies [20-22].
Another finding of interest in the current study is that
the prevalence of early or late MNC apoptosis in circula-
tion was significantly augmented in DVT rats compared
to that in the SC animals by days 2 and 14 after DVT-
induction procedure. We suggest that these phenomena
were caused by thrombus-induced generation of ROS
and oxidative stress as well as the augmentation of in-
flammatory response that, in turn, participated in MNC
damage. Recent studies [25,26] have shown that tissue
damage elicits inflammatory reaction and activation of
complement cascade, thereby causing further tissue dam-
age/cell death, and irreversible MNC apoptosis in systemic
circulation in the setting of acute arterial occlusive syn-
drome. In this way, our findings are compatible with those
of previous studies [25,26]. Furthermore, the incidence of
cellular apoptosis was significantly reduced in DVT ani-
mals after rosuvastatin treatment. Therefore, our findings
reinforced those of recent reports [25,26].
Thrombomodulin, which was originally identified in
vascular endothelial cells, is an integral membrane
protein widely expressed in a variety of cell types. Its
physiological importance lies in its role as a cofactor for
thrombin and its ability to suppress blood coagulation
by converting thrombin into an anticoagulant enzyme
from a procoagulant enzyme [27]. Thrombomodulin has
been identified to possess indirect anti-inflammatory
property [28,29]. Based on the results of previous studies
[27-29] and the association between inflammation and
enhancement of thrombus formation [11-15], we propose
that the augmented cellular expression of thrombomodulin
in DVT animals in the current study was the result of an
enhancement of thrombomodulin generation in response
to the inflammation and formation of thrombosis elicited
by stenosis of IVC. Accordingly, our findings, in addition
to supporting those of previous studies [11-15,27-29],
could, at least in part, explain the effect of rosuvastatin
treatment on attenuating thrombomodulin expression in
IVC endothelial cells through suppressing the expressions
of these inflammatory and oxidative biomarkers.
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This study has limitations. First, the therapeutic dosage
of rosuvastatin in the current study was based on our
previous report [16]. The effects of different dosages of
rosuvastatin on its effectiveness in reducing the thrombus
burden, however, were not investigated. Therefore, this
study does not provide an optimal rosuvastatin dosage
that produces maximal therapeutic impact with minimal
side effects. Second, this study did not completely rule out
that the model used in this work might carry a variation
in thrombus burden, making this model vulnerable when
treatment options were evaluated. Third, this study did
not completely rule out the possibility of procedure-
related infection that would induce an increase in the cir-
culating number of immune cells. Additionally, this study
did not measure the different sample site for circulating
numbers of blood counts, neutrophils and CD11b that
have been reported to be readily influenced by different
sites of measurement [30]. Finally, although the present
study provided copious data, the exact mechanisms by
which rosuvastatin suppressed thrombus formation in
IVC remain unclear.
Conclusion
The results of the present study highlight that DVT aug-
mented inflammation, ROS generation, and oxidative
stress that are associated with an increased thrombus
burden. On the other hand, rosuvastatin treatment sig-
nificantly reduced thrombus burden in the IVC in a ro-
dent model of DVT.
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